The present invention relates to the use of isolithocholic acid (isoLCA) in the prevention or treatment of inflammatory respiratory diseases and/or the prevention or treatment of diseases associated with cytokine storm. The therapeutic effect is primarily driven by the effective inhibition of neutrophil influx into respiratory tissues—one of the central contributors to epithelial damage, mucus hypersecretion, and disease progression in neutrophil-dominant conditions. At the molecular level, isoLCA compounds suppress the production of multiple pro-inflammatory cytokines and chemokines, including CXCL1, CCL2, CCL5, CXCL10, and IL-6. These mediators play critical roles in leukocyte recruitment, amplification of inflammatory cascades, and the development of cytokine storm syndromes.

The formulation is optimized for intranasal administration, enabling localized delivery directly to the respiratory tract. The invention is particularly suited for respiratory diseases associated with neutrophilia and dysregulated cytokine responses, including: acute respiratory distress syndrome (ARDS), viral respiratory infections, bacterial respiratory infections, neutrophilic asthma, chronic obstructive pulmonary disease (COPD), Bronchiectasis, idiopathic pulmonary fibrosis (IPF).

Nencki Institute is the sole applicant.

For more information contact Technology Transfer Office.